8-K: Mangoceuticals Amends Preferred Stock Terms and Equity Incentive Plan

Mangoceuticals modifies the conversion price and other terms of its Series B Convertible Preferred Stock and approves a second amendment to its 2022 Equity Incentive Plan.

Summary

• Mangoceuticals, Inc. held a special meeting on March 17, 2025, where stockholders approved several key proposals.
• These included amendments to the Series B Convertible Preferred Stock, reducing the conversion price to $1.50 per share and removing dividend rights.
• Stockholders also approved a second amendment to the 2022 Equity Incentive Plan, increasing the share reserve and incentive stock option limit.
• Additionally, the issuance of shares of Mango & Peaches, a wholly-owned subsidiary, to CEO Jacob Cohen was approved.
• The amendment to the Series B preferred stock designation reduces the conversion and floor price from $2.25 to $1.50 per share.
• The amendment also removes dividend rights, except for standard participatory rights for dividends declared on the company's common stock.
• The company submitted the amendment to the Certificate of Designations to the Secretary of the State of Texas on March 17, 2025.
• The Second Amendment to the 2022 Equity Incentive Plan increases the aggregate number of shares of common stock that may be issued pursuant to awards to 10,000,000 shares.
• The plan includes an automatic increase on April 1st of each year for six years commencing on April 1, 2026, and ending on April 1, 2032, in an amount equal to the lesser of (x) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; and (y) 2,000,000 shares of common stock.
• No more than a total of 26,000,000 shares of common stock (or awards) may be issued or granted under the 2022 Plan in aggregate, and no more than 26,000,000 shares of common stock may be issued pursuant to the exercise of Incentive Stock Options.

Sentiment

Score: 7

Explanation: The document reflects standard corporate actions (amendments to stock and equity plans) that are generally viewed neutrally to slightly positively as they can improve the company's ability to attract talent and manage its capital structure.

Positives

• The reduction in the conversion price of the Series B Convertible Preferred Stock may make it more attractive to investors.
• The removal of dividend rights simplifies the capital structure.
• The increase in the share reserve for the 2022 Equity Incentive Plan provides more flexibility for attracting and retaining employees, officers, directors and consultants.

Negatives

• The removal of dividend rights for the Series B Convertible Preferred Stock may be viewed negatively by some investors.

Risks

• The potential issuance of a significant number of shares under the 2022 Equity Incentive Plan could dilute existing shareholders.
• The conversion of the Series B Convertible Preferred Stock could also lead to dilution.

Future Outlook

The company has not provided specific financial guidance in this report. The amendments to the equity incentive plan suggest a continued focus on using equity-based compensation.

Industry Context

Companies often adjust their equity incentive plans and preferred stock terms to remain competitive in attracting talent and managing their capital structure. These changes are fairly common and reflect the company's evolving needs.

Comparison to Industry Standards

• The use of equity incentive plans is standard practice across the industry to align employee and shareholder interests.
• The specific terms of the plan, such as the number of shares reserved and the types of awards offered, are comparable to those of similar-sized companies in the pharmaceutical sector.
• The conversion price adjustment of the preferred stock is a strategic move that can be compared to similar actions taken by other companies to optimize their capital structure and attract investment.

Related Party Transactions

• The issuance of shares of the common stock and Series A Super Majority Voting Preferred Stock of Mango & Peaches, the company's wholly-owned subsidiary, to CEO Jacob Cohen was approved by stockholders.

Stakeholder Impact

• Shareholders may experience dilution from the conversion of preferred stock and the issuance of shares under the equity incentive plan.
• Employees, officers, directors and consultants may benefit from the amended equity incentive plan.
• The changes to the Series B Convertible Preferred Stock may impact the rights and value of those securities.

Next Steps

• The company will continue to administer the 2022 Equity Incentive Plan according to the amended terms.
• The company will monitor the conversion of the Series B Convertible Preferred Stock.

Key Dates